David P. Nicolau

Hartford Hospital — United States

Medicine · Health Sciences

71h-index24.1kcitations931works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotics Pharmacokinetics and Efficacy(640), Antibiotic Resistance in Bacteria(503), Pneumonia and Respiratory Infections(280), Antibiotic Use and Resistance(197), Antimicrobial Resistance in Staphylococcus(133)

Publications923 total

Impact of meticillin-resistant Staphylococcus aureus rapid molecular testing on hospital-related quality and cost of care
Journal of Hospital Infection·2025Open Access
Efficacy of human-simulated aztreonam-avibactam against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine thigh infection model
Journal of Antimicrobial Chemotherapy·2025
Monoclonal antibodies protect against pandrug-resistant Klebsiella pneumoniae
Nature·2025· 3 cited
Sulbactam-durlobactam in combination with aztreonam and carbapenems against carbapenem-resistant <i>Acinetobacter baumannii</i> : an assessment using the MIC-based broth disk elution
Journal of Clinical Microbiology·2025Open Access
Non-<i>Klebsiella pneumoniae</i> Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: <i>Burkholderia cepacia</i> Complex, <i>Stenotrophomonas maltophilia</i>, and <i>Acinetobacter baumannii</i>
Clinical Infectious Diseases·2025· 1 cited
Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains isolated from respiratory and bloodstream sources: results from ACNBio study
Antimicrobial Agents and Chemotherapy·2025· 4 citedOpen Access
An <i>ex vivo</i> model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
Journal of Antimicrobial Chemotherapy·2025· 1 cited
Quantification of sulbactam and durlobactam in saline and human plasma via ultra-performance liquid chromatography tandem mass spectrometry
Journal of Chromatography B·2025· 2 cited
Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy·2025· 4 citedOpen Access
Meropenem–Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence
Infectious Diseases and Therapy·2025· 6 citedOpen Access
Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of <i>Enterobacterales</i> from outpatient centers and nursing homes across the United States (2022–2024)
Antimicrobial Agents and Chemotherapy·2025· 2 citedOpen Access
Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in a standardized neutropenic murine pneumonia model
Journal of Antimicrobial Chemotherapy·2025· 1 citedOpen Access
Cefiderocol pharmacokinetics in critically-ill patients receiving extra-corporeal membrane oxygenation (ECMO)
International Journal of Antimicrobial Agents·2025· 2 cited
P-1653. Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) across Outpatient and Urgent Care Visits
Open Forum Infectious Diseases·2025Open Access
P-1220. Humanizing Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures of Cefiderocol in Standardized Murine Lung Infection Model
Open Forum Infectious Diseases·2025Open Access
P-1221. Benchmark Efficacy for Humanized Cefiderocol Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against Gram Negative Isolates in Standardized Murine Lung Infection Model
Open Forum Infectious Diseases·2025Open Access
P-1217. Validation of Cefiderocol (FDC) Package Insert Dosing Recommendation for Patients receiving Continuous Renal Replacement Therapy (CRRT): A Prospective Multi-Center Pharmacokinetic Study
Open Forum Infectious Diseases·2025Open Access
P-1226. Dose Optimization of β-lactams against Carbapenem-Resistant Pseudomonas from Turkiye Defined as Susceptible to Ceftazidime, Cefepime or Piperacillin/Tazobactam
Open Forum Infectious Diseases·2025Open Access
P-1219. Benchmarks for Humanized Meropenem Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against <i>Klebsiella pneumoniae</i> in Standardized Murine Lung Infection Model
Open Forum Infectious Diseases·2025Open Access
An antibiotic stewardship initiative focused on community-acquired bacterial pneumonia (CABP) in outpatient clinics and urgent care centers: a 2023–2024 community health system experience
Antimicrobial Stewardship & Healthcare Epidemiology·2025Open Access
page 1 of 47Next →

Frequent Co-authors

Joseph L. Kuti(19), Charles H. Nightingale(10), Jared L. Crandon(7), Richard Quintiliani(5), Chonghua Li(3), Melinda K. Lacy(3), Catharine C. Bulik(3), Matteo Bassetti(3), Anthony M. Nicasio(3), Eric Shore(3), Paul Belliveau(2), Jack Ross(2), C H Nightingale(2), Pamela R. Tessier(2), Mario Tumbarello(2), Garyphallia Poulakou(2), JoCarol McNabb(2), Shawn H. MacVane(2), Debra Mansfield(2), Adrian Dana(2)